Halozyme Therapeutics, Inc. (HALO)
$
62.22
+0.32 (0.51%)
Key metrics
Financial statements
Free cash flow per share
5.1391
Market cap
7.3 Billion
Price to sales ratio
5.8867
Debt to equity
2.9980
Current ratio
1.5871
Income quality
1.0260
Average inventory
183.7 Million
ROE
1.4155
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally, focusing on advancing drug delivery technologies. The company recorded an operating income of $551,475,000.00 reflecting its earnings from core operations, while incurring an interest expense of $18,095,000.00 indicative of its debt servicing obligations. The total costs and expenses for the company are $463,849,000.00 highlighting its overall spending. Additionally, the diluted EPS is $3.43 accounting for potential share dilution, and the company incurred an income tax expense of $113,041,000.00 indicating its tax obligations. Its flagship product, Hylenex recombinant, utilizes patented recombinant human hyaluronidase enzyme (rHuPH20) to facilitate subcutaneous fluid administration, enhancing the dispersion and absorption of other injected drugs. The company develops several important therapeutics including Perjeta, RITUXAN HYCELA, and MabThera SC for non-Hodgkin lymphoma, as well as HYQVIA for immunodeficiency disorders. Furthermore, collaborations with several renowned organizations support its innovative efforts in treating various conditions. The stock is affordable at $77.81 suitable for budget-conscious investors, which, combined with a high average trading volume of 2,676,142.50 indicates strong liquidity. With a mid-range market capitalization of $7,316,297,355.00 the company is a steady performer in the competitive landscape of the Biotechnology industry. As a key player in this sector, it significantly contributes to the overall market landscape, driving innovation and growth. In addition to its successful products, the company is actively developing treatments such as Tecentriq for non-small cell lung cancer and OCREVUS for multiple sclerosis, alongside other promising therapies aimed at a variety of serious health conditions. Halozyme's extensive collaborations with top pharmaceutical companies also underscore its commitment to addressing unmet medical needs and advancing healthcare outcomes globally.
Is Halozyme Therapeutics, Inc. (HALO) a good investment?
Investing in Halozyme Therapeutics, Inc. (HALO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Halozyme Therapeutics, Inc. (HALO)'s stock forecast?
Analysts predict Halozyme Therapeutics, Inc. stock to fluctuate between $46.26 (low) and $79.50 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Halozyme Therapeutics, Inc.'s market capitalization?
As of 2025-12-12, Halozyme Therapeutics, Inc.'s market cap is $7,316,297,355, based on 117,597,000 outstanding shares.
How does Halozyme Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Halozyme Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Halozyme Therapeutics, Inc. (HALO) stock?
To buy Halozyme Therapeutics, Inc. (HALO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for HALO. Place an order (Market, Limit, etc.).
What is the best time to invest in Halozyme Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Halozyme Therapeutics, Inc. perform in the last earnings report?
Revenue: $1,015,324,000 | EPS: $3.50 | Growth: 64.32%.
Where can I find Halozyme Therapeutics, Inc.'s investor relations reports?
Visit https://www.halozyme.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Halozyme Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Halozyme Therapeutics, Inc. stock?
All-time high: $79.50 (2025-09-23) | All-time low: $29.85 (2023-05-09).
What are the key trends affecting Halozyme Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Halozyme is upgraded to a near-term Buy, driven by robust 2025–2028 royalty visibility and conservative valuation. HALO's acquisition of Elektrofi (Hypercon) extends IP into the 2040s, offering optionality but with uncertain long-term revenue durability. ENHANZE's U.S. patent expiry in 2027 raises post-2030 questions, but royalty streams and asset-light margins remain strong near-term.
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
fool.com
Halozyme Therapeutics is a leader in the subcutaneous drug delivery niche, generating gobs of free cash flow. The company faces patent cliffs ahead for its core products and is actively trying to diversify its offerings.
wsj.com
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
prnewswire.com
SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany. The Munich Regional Court's 7th Civil Division found that there is imminent infringement for Keytruda SC in Germany regarding one of Halozyme's MDASE™ patents in Europe, European Patent No.
zacks.com
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
seekingalpha.com
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript
zacks.com
Halozyme Therapeutics (HALO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
prnewswire.com
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier SAN DIEGO , Nov. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the successful completion of its acquisition of Elektrofi, Inc. ("Elektrofi"), a biopharmaceutical company with a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon™. The transaction follows the expiration of the Hart-Scott-Rodino waiting period and satisfaction of all closing conditions.
See all news
